In 2005 and 2006, GSK secretly conducted an analysis of the cardiovascular safety of Avandia and concluded that the drug increased the risk of heart attacks and related events by about 30%.
FORBES: Steven Nissen: The Hidden Agenda Behind The FDA's New Avandia Hearings